Novabay Pharmaceuticals Inc (AMEX:NBY)’s traded shares stood at 1.12 million during the last session, with the company’s beta value hitting 0.67. At the close of trading, the stock’s price was $0.57, to imply an increase of 4.98% or $0.03 in intraday trading. The NBY share’s 52-week high remains $9.08, putting it -1492.98% down since that peak but still an impressive 36.84% since price per share fell to its 52-week low of $0.36. The company has a valuation of $2.77M, with an average of 0.15 million shares in intraday trading volume over the past 10 days and average of 455.58K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Novabay Pharmaceuticals Inc (NBY), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give NBY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novabay Pharmaceuticals Inc (AMEX:NBY) trade information
After registering a 4.98% upside in the last session, Novabay Pharmaceuticals Inc (NBY) has traded red over the past five days. The 5-day price performance for the stock is 15.67%, and -8.87% over 30 days. With these gigs, the year-to-date price performance is -92.06%. Short interest in Novabay Pharmaceuticals Inc (AMEX:NBY) saw shorts transact 73168.0 shares and set a 0.07 days time to cover.
Novabay Pharmaceuticals Inc (NBY) estimates and forecasts
Looking at statistics comparing Novabay Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Novabay Pharmaceuticals Inc (NBY) shares are -76.77% down over the last 6 months, with its year-to-date growth rate higher than industry average at 99.85% against 16.40%. The rating firms project that company’s revenue will shrink -32.77% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 2.5M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 3M.Earnings reports from the last fiscal year show that sales brought in 3.73M and 2.63M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -32.92% before jumping 14.03% in the following quarter.
NBY Dividends
Novabay Pharmaceuticals Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Novabay Pharmaceuticals Inc (AMEX:NBY)’s Major holders
Novabay Pharmaceuticals Inc insiders hold 0.02% of total outstanding shares, with institutional holders owning 2.58% of the shares at 2.58% float percentage. In total, 2.58% institutions holds shares in the company, led by NVWM, LLC.
